Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | ARG1 | P05089 | 1/20 | 0.41 |
| ▸ | ARG2 | P78540 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | PPARD | Q03181 | 4/20 | 0.41 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31018949 | 0.98 | SMPD1 (0.50) | FDPSSMPD1CES2PPARGPPARD | |
| SCHEMBL14931594 | 0.98 | SMPD1 (0.50) | FDPSSMPD1CES2PPARGPPARD | |
| SCHEMBL20599006 | 0.98 | SMPD1 (0.50) | FDPSSMPD1CES2PPARGPPARD | |
| SCHEMBL287722 | 0.98 | SMPD1 (0.50) | FDPSSMPD1CES2PPARGPPARD | |
| SCHEMBL4421180 | 0.98 | SMPD1 (0.50) | FDPSSMPD1CES2PPARGPPARD | |
| SCHEMBL1027737 | 0.98 | SMPD1 (0.50) | FDPSSMPD1CES2PPARGPPARD | |
| SCHEMBL288685 | 0.93 | FDPS (0.46) | FDPSSMPD1AKR1B1ARG1ARG2 | |
| Propionic Acid SCHEMBL7632408 | 0.92 | SMPD1 (0.46) | FDPSSMPD1PPARGPPARDPPARA | |
| Hydrochloric Acid SCHEMBL28391923 | 0.91 | FDPS (0.45) | FDPSSMPD1AKR1B1ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL27328297 | 0.91 | FDPS (0.45) | FDPSSMPD1AKR1B1ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118497101-B | Recombinant escherichia coli without auxotrophy and plasmid for producing L-homoserine and application thereof | 中国科学院微生物研究所 | 2024-10-25 | — | — | CN | claimed |
| CN-118685334-A | Engineering bacterium for producing L-isoleucine and construction method and application thereof | 中国科学院微生物研究所 | 2024-09-24 | — | — | CN | claimed |
| CN-118497101-A | Recombinant escherichia coli without auxotrophy and plasmid for producing L-homoserine and application thereof | 中国科学院微生物研究所 | 2024-08-16 | — | — | CN | claimed |
| CN-118388598-A | Labeling precursor, probe, preparation method and application thereof | 苏州大学附属第一医院 | 2024-07-26 | — | — | CN | claimed |
| CN-113956992-B | L-homoserine tolerant escherichia coli and application thereof | 中国科学院微生物研究所 | 2023-09-01 | — | — | CN | claimed |
| WO-2022257757-A1 | DAPB GENE-BASED POLYNUCLEOTIDE HAVING PROMOTER ACTIVITY AND USE THEREOF | 中国科学院天津工业生物技术研究所 | 2022-12-15 | — | — | WO | claimed |
| CN-112725251-B | Engineering bacterium for producing spermidine | 江南大学 | 2022-07-22 | — | — | CN | claimed |
| CN-113122487-B | Recombinant bacterium for high yield of L-homoserine, and preparation method and application thereof | 中国科学院微生物研究所 | 2022-05-24 | — | — | CN | claimed |
| EP-2499148-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2012-09-19 | — | — | EP | claimed |
| US-8192976-B2 | Biological synthesis of difunctional alkanes from carbohydrate feedstocks | CELEXION, LLC (US) | 2012-06-05 | — | — | US | claimed |
| US-8133704-B2 | Biological synthesis of difunctional alkanes from carbohydrate feedstocks | CELEXION, LLC (US) | 2012-03-13 | — | — | US | claimed |
| CN-102317464-A | From alpha-ketoacid biosynthesizing difunctionality alkane | CELEXION LLC | 2012-01-11 | — | — | CN | claimed |
| US-20110171696-A1 | Biological Synthesis of Difunctional Alkanes from Carbohydrate Feedstocks | CELEXION, LLC (US) | 2011-07-14 | — | — | US | claimed |
| WO-2011014973-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2011-02-10 | — | — | WO | claimed |
| EP-1077692-B1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2004-07-28 | — | — | EP | claimed |
| EP-1077692-A1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | Warner-Lambert Company LLC (US) | 2001-02-28 | — | — | EP | claimed |
| WO-1999059573-A9 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2000-05-04 | — | — | WO | claimed |
| WO-1999059573-A1 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER-LAMBERT COMPANY (US) | 1999-11-25 | — | — | WO | claimed |
| US-5352453-A | Acidic ph | BOEHRINGER MANNHEIM GMBH (DE) | 1994-10-04 | — | — | US | claimed |
| US-20250340587-A1 | INSOLUBLE SUPPORT FOR SOLID PHASE SYNTHESIS | POLYPEPTIDE LABORATORIES HOLDING PPL AB (SE) | 2025-11-06 | — | — | US | disclosed |
| US-12383522-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | AMNEAL PHARMACEUTICALS LLC (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250129126-A1 | LONG-LASTING HEPATITIS VIRUS ENTRY INHIBITOR | Chengdu AODA Biotechnology Co., Ltd (CN) | 2025-04-24 | — | — | US | disclosed |
| EP-4532509-A1 | INSOLUBLE SUPPORT FOR SOLID PHASE SYNTHESIS | Polypeptide Laboratories Holding (PPL) AB (SE) | 2025-04-09 | — | — | EP | disclosed |
| WO-2024255806-A1 | PREPARATION AND USE OF HYDROGEL | 粤港澳大湾区精准医学研究院(广州) | 2024-12-19 | — | — | WO | disclosed |
| CN-119144151-A | Preparation of hydrogels and uses thereof | 粤港澳大湾区精准医学研究院(广州) | 2024-12-17 | — | — | CN | disclosed |
| CN-118497101-B | Recombinant escherichia coli without auxotrophy and plasmid for producing L-homoserine and application thereof | 中国科学院微生物研究所 | 2024-10-25 | — | — | CN | disclosed |
| CN-118685334-A | Engineering bacterium for producing L-isoleucine and construction method and application thereof | 中国科学院微生物研究所 | 2024-09-24 | — | — | CN | disclosed |
| CN-118497101-A | Recombinant escherichia coli without auxotrophy and plasmid for producing L-homoserine and application thereof | 中国科学院微生物研究所 | 2024-08-16 | — | — | CN | disclosed |
| CN-118388598-A | Labeling precursor, probe, preparation method and application thereof | 苏州大学附属第一医院 | 2024-07-26 | — | — | CN | disclosed |
| CN-118286386-A | Application of NOD1 agonist in preparation of medicines for treating hepatocellular carcinoma | 复旦大学附属中山医院 | 2024-07-05 | — | — | CN | disclosed |
| EP-4392071-A1 | METHOD OF SYNTHESIZING DENDRIMERIC AMPHIPHILE | Kaohsiung Medical University (TW) | 2024-07-03 | — | — | EP | disclosed |
| US-11931328-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | AMNEAL PHARMACEUTICALS LLC (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240082193-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | AMNEAL PHARMACEUTICALS LLC (US) | 2024-03-14 | — | — | US | disclosed |
| US-11850225-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | AMNEAL PHARMACEUTICALS LLC (US) | 2023-12-26 | — | — | US | disclosed |
| WO-2023234837-A1 | INSOLUBLE SUPPORT FOR SOLID PHASE SYNTHESIS | POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) | 2023-12-07 | — | — | WO | disclosed |
| CN-113956992-B | L-homoserine tolerant escherichia coli and application thereof | 中国科学院微生物研究所 | 2023-09-01 | — | — | CN | disclosed |
| CN-108456669-B | Ribosome binding site, recombinant expression plasmid, transformant and application thereof | 上海凯赛生物技术股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-108456668-B | Ribosome binding site, recombinant expression plasmid, transformant and application thereof | 上海凯赛生物技术股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20230218554-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | AMNEAL PHARMACEUTICALS LLC (US) | 2023-07-13 | — | — | US | disclosed |
| EP-3611254-B1 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF HEXAMETHYLENEDIAMINE | GENOMATICA INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11654124-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | AMNEAL PHARMACEUTICALS LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230103372-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | AMNEAL PHARMACEUTICALS LLC (US) | 2023-04-06 | — | — | US | disclosed |
| WO-2023055457-A1 | BACLOFEN-CONTAINING GRANULE FORMULATIONS AND REDUCED PATIENT EXPOSURE TO METABOLITE VARIATIONS | AMNEAL PHARMACEUTICALS LLC (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023023889-A1 | METHOD OF SYNTHESIZING DENDRIMERIC AMPHIPHILE | KAOHSIUNG MEDICAL UNIVERSITY (CN) | 2023-03-02 | — | — | WO | disclosed |
| US-11591366-B2 | Macrocyclic compounds and methods of preventing or treating pain | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2023-02-28 | — | — | US | disclosed |
| WO-2022257757-A1 | DAPB GENE-BASED POLYNUCLEOTIDE HAVING PROMOTER ACTIVITY AND USE THEREOF | 中国科学院天津工业生物技术研究所 | 2022-12-15 | — | — | WO | disclosed |
| US-11491125-B1 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | AMNEAL PHARMACEUTICALS LLC (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220308068-A1 | BIOMARKER IN OSTEOPOROSIS INTERVENTION THERAPY BY BONE PEPTIDE, SCREENING METHOD AND USE THEREOF | Institute of Food Science and Technology, Chinese Academy of Agricultural Sciences (CN) | 2022-09-29 | — | — | US | disclosed |
| US-20220265588-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | AMNEAL PHARMACEUTICALS LLC (US) | 2022-08-25 | — | — | US | disclosed |
| CN-109790557-B | Controlling biofilm dispersion to produce amino acids or amino acid-derived products | 上海凯赛生物技术股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-108977373-B | Bacillus terracotta cotta HMD9161 and microbial inoculum and application thereof | 中国热带农业科学院热带生物技术研究所 | 2022-06-28 | — | — | CN | disclosed |
| EP-4003323-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | Saol International Research Ltd. (BM) | 2022-06-01 | — | — | EP | disclosed |
| CN-113122487-B | Recombinant bacterium for high yield of L-homoserine, and preparation method and application thereof | 中国科学院微生物研究所 | 2022-05-24 | — | — | CN | disclosed |
| CN-114450002-A | Stable formulations of 4-amino-3-substituted butyric acid derivatives | 萨欧国际研究有限公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-111662918-B | Co-production method of multi-protein system, co-production system of multi-protein system and application | 深圳先进技术研究院 | 2022-04-22 | — | — | CN | disclosed |
| CN-111621511-B | Co-production method of multi-protein system, circulating co-production system of multi-protein system and application | 中国科学院深圳先进技术研究院 | 2022-04-08 | — | — | CN | disclosed |
| CN-113956992-A | L-homoserine-tolerant escherichia coli and application thereof | 中国科学院微生物研究所 | 2022-01-21 | — | — | CN | disclosed |
| WO-2021237410-A1 | CO-PRODUCTION METHOD FOR MULTIPROTEIN SYSTEM, CO-PRODUCTION SYSTEM FOR MULTIPROTEIN SYSTEM AND USE THEREOF | 深圳先进技术研究院 | 2021-12-02 | — | — | WO | disclosed |
| WO-2021237411-A1 | CO-PRODUCTION METHOD FOR MULTI-PROTEIN SYSTEM, CYCLIC CO-PRODUCTION SYSTEM FOR MULTI-PROTEIN SYSTEM, AND USE | 中国科学院深圳先进技术研究院 | 2021-12-02 | — | — | WO | disclosed |
| CN-106661418-B | Adhesive agent | 克瑙夫绝缘私人有限公司 | 2021-07-09 | — | — | CN | disclosed |
| WO-2021021277-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | SAOL INTERNATIONAL LIMITED (BM) | 2021-02-04 | — | — | WO | disclosed |
| US-10792262-B1 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | SAOL INTERNATIONAL LIMITED (BM) | 2020-10-06 | — | — | US | disclosed |
| CN-111662918-A | Co-production method of multi-protein system, co-production system of multi-protein system and application | 深圳先进技术研究院 | 2020-09-15 | — | — | CN | disclosed |
| CN-111621511-A | Co-production method of multi-protein system, circulating co-production system of multi-protein system and application | 中国科学院深圳先进技术研究院 | 2020-09-04 | — | — | CN | disclosed |
| US-10751312-B1 | — | — | 2020-08-25 | — | — | US | disclosed |
| US-20180362582-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF PREVENTING OR TREATING PAIN | UNIVERSITé DE SHERBROOKE (CA) | 2018-12-20 | — | — | US | disclosed |
| CN-104745650-B | For the preparation method for the reference state glutamine for improving nutrients in intestine of young pigs | 郑州新威营养技术有限公司 | 2018-02-02 | — | — | CN | disclosed |
| WO-2017134148-A1 | SELECTIVE CELL PENETRATING PEPTIDES | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2017-08-10 | — | — | WO | disclosed |
| EP-3146010-A1 | BINDERS | Knauf Insulation, Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| WO-2015177114-A1 | BINDERS | KNAUF INSULATION, LLC (US) | 2015-11-26 | — | — | WO | disclosed |
| WO-2012177721-A1 | MICROORGANISMS FOR PRODUCING 6-AMINOCAPROIC ACID | GENOMATICA, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| EP-2427476-A1 | BETA-HAIRPIN PEPTIDOMIMETICS HAVING CXCR4 ANTAGONIZING ACTIVITY | Polyphor Ag (CH) | 2012-03-14 | — | — | EP | disclosed |
| CN-102317464-A | From alpha-ketoacid biosynthesizing difunctionality alkane | CELEXION LLC | 2012-01-11 | — | — | CN | disclosed |
| WO-2010127704-A1 | BETA-HAIRPIN PEPTIDOMIMETICS HAVING CXCR4 ANTAGONIZING ACTIVITY | POLYPHOR AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| WO-2009078040-A2 | COMPOUNDS INDUCING REPERFUSION IN ISCHAEMIC TISSUES | DATTA DEBATOSH (IN) | 2009-06-25 | — | — | WO | disclosed |
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | disclosed |
| EP-1077692-B1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2004-07-28 | — | — | EP | disclosed |
| EP-1261611-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-12-04 | — | — | EP | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |
| EP-1077692-A1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | Warner-Lambert Company LLC (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
| WO-1999059573-A9 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-1999059573-A1 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER-LAMBERT COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999059573-A1 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER-LAMBERT COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10792262-B1 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | ABAT, GABRA6, BCAT2 | FDPS 901/4885SMPD1 2389/4885AKR1B1 2981/4885 |
| US-11654124-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | GABRA6, GABBR1, GABBR2 | FDPS 1981/4885SMPD1 3541/4885AKR1B1 1372/4885 |
| US-20240082193-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | GABRB1, GABRB2, GABBR1 | FDPS 3340/4885SMPD1 982/4885AKR1B1 203/4885 |
| US-20250340587-A1 | INSOLUBLE SUPPORT FOR SOLID PHASE SYNTHESIS | SSU72, CPSF6, IDUA | FDPS 986/4885SMPD1 3116/4885AKR1B1 3412/4885 |
| US-20220265588-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | GABRA6, GABBR1, GABBR2 | FDPS 1981/4885SMPD1 3541/4885AKR1B1 1372/4885 |
| US-11591366-B2 | Macrocyclic compounds and methods of preventing or treating pain | COX15, ACHE, TRPV1 | FDPS 1257/4885SMPD1 3044/4885AKR1B1 398/4885 |
| US-20180362582-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF PREVENTING OR TREATING PAIN | COX15, ACHE, TRPV1 | FDPS 1257/4885SMPD1 3044/4885AKR1B1 398/4885 |
| US-12383522-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | GABRB1, GABRB2, GABBR1 | FDPS 3340/4885SMPD1 982/4885AKR1B1 203/4885 |
| US-11931328-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | GABRA6, GABBR1, GABBR2 | FDPS 1981/4885SMPD1 3541/4885AKR1B1 1372/4885 |
| US-11491125-B1 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | GABRB1, GABRB2, GABBR1 | FDPS 3340/4885SMPD1 982/4885AKR1B1 203/4885 |
| US-11850225-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | GABRB1, GABRB2, GABBR1 | FDPS 3364/4885SMPD1 1069/4885AKR1B1 208/4885 |
| US-20230218554-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | GABRA6, GABBR1, GABBR2 | FDPS 1981/4885SMPD1 3541/4885AKR1B1 1372/4885 |
| US-20230103372-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | GABRB1, GABRB2, GABBR1 | FDPS 3364/4885SMPD1 1069/4885AKR1B1 208/4885 |
| US-10751312-B1 | — | LIPA, CEL, GANC | FDPS 781/4885SMPD1 109/4885AKR1B1 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.